Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting

Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting Company will also present new preclinical data for its orthoIL-2 technology for cytokine-inducible cell therapies MENLO PARK, CA – March 7, 2024 – Synthekine Inc ., an engineered cytokine therapeutics company, today announced that data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK-012, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, from April 5-10, 2024. The company will also present new preclinical data for its orthogonal IL-2 ( ortho IL-2) technology for cytokine-inducible cell therapies, currently being investigated in a Phase 1 study with the STK-009 + SYNCAR-001 combination therapy. “AACR marks the first time Synthekine will present clinical data from the ongoing trial of STK-012, our lead program and a novel approach to biasing IL-2,” said Debanjan Ray, chief executive officer of Synthekine. “We are also excited to share new preclinical data with our ortho IL-2 technology comparing it head-to-head with other armoring approaches for CAR T-cell therapies. We look forward to sharing these results with the scientific community, while continuing our rapid progress to advance our broad pipeline of cytokine programs, including cytokine-inducible cell therapies, for the treatment of cancer, inflammatory and autoimmune diseases.” Details are as follows and available on the AACR online itinerary planner: Title: Initial results from a Phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132) Session Title: First-in-Human Phase I Clinical Trials 2 Session Date & Time: Tuesday, Apr 9, 2024, 9:00 AM – 12:30 PM PT Location: Poster Section 48 Poster Board Number : 11 Abstract Number: CT183 Title: Orthogonal IL-2/IL-2Rβ signaling selectively enhances and sustains a synthetic effector state via a novel mechanism and outperforms constitutive armoring approaches Session Title: Adoptive Cellular Therapy 2 Session Date & Time: Tuesday, Apr 9, 2024, 1:30 PM – 5:00 PM PT Location: Poster Section 40 Poster Board Number: 3 Abstract Number: 6312 Copies of the posters will be available on Synthekine’s website following presentation at the meeting. About Synthekine Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists. For more information, visit www.www.synthekine.com , and follow us on X @synthekine and LinkedIn . Contact: Will Zasadny Inizio Evoke Comms 619-961-8848 [email protected] Back to News About Us Our Story About Cytokines Leadership Team Board of Directors Our Partners Our Pipeline Pipeline STK-012 Legacy Programs Cytokine Engineering Platforms For Patients SYNERGY-101 Phase 2 Study in Non-Small Cell Lung Cancer Expanded Access Policy News Press Releases Posters and Publications Twitter Linked In Careers Contact Copyright 2026 – Synthekine | Privacy Policy | Cookie Preferences

The release as fetched from its publisher. synthekine.com ↗